Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HLX22 plus trastuzumab and XELOX with or without pembrolizumab in first-line HER2-positive advanced gastric or gastroesophageal junction cancer
2024-516633-12-00Phase 3Authorised
- Sponsor
- Henlius
- Start
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma comparing HLX22 combination arm with Placebo control combination arm (2 arms). Primary endpoints: Progression-free survival and Overall survival. Planned start Jun 2025; status: authorised.
02
Drugs
hlx22
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-516633-12-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516633-12-00.